COVID-19: Antiviral Combo Clears Virus in Immunocompromised Patients | New Study

For individuals with weakened immune systems and persistent COVID-19 infections, a new study offers encouraging evidence that combining antiviral medications can lead to viral clearance. Researchers found that combined antiviral therapy resulted in satisfactory clinical and microbiological outcomes in a small group of oncohematological patients with prolonged SARS-CoV-2 infection.

The Challenge of Persistent COVID-19 in Immunocompromised Patients

While many people recover from COVID-19 within weeks, some, particularly those with compromised immune systems, can experience persistent infections lasting for months. This prolonged viral shedding not only increases the risk of developing severe illness but also raises concerns about the potential for viral evolution and the emergence of new variants. The study, published in January 2026 in Emerging Infectious Diseases, focused on patients undergoing treatment for blood cancers, a population particularly vulnerable to prolonged COVID-19.

Study Design and Findings

The retrospective cohort study, conducted between October 2021 and December 2024, examined the outcomes of 15 patients with persistent SARS-CoV-2 infection who received combined antiviral treatments. These patients had either tested positive for SARS-CoV-2 for more than 14 days despite initial antiviral therapy, or required viral clearance before undergoing potentially immunosuppressive treatments like hematopoietic progenitor transplantation or chemo-immunotherapy.

The combined antiviral therapies used varied, including dual and triple combinations. In 13 out of 15 episodes analyzed, viral clearance was achieved 10 to 69 days after initiating the combination therapy. Researchers analyzed samples with high viral loads (Ct value < 32) using whole-genome sequencing. Importantly, the therapy proved effective even in cases where resistance mutations had emerged *before* the start of combination treatment.

The study also highlighted the importance of accurate diagnosis. Genomic analysis revealed one patient initially believed to have a persistent infection was, in fact, experiencing repeated reinfections that had been misdiagnosed. This underscores the need for careful genomic surveillance to differentiate between persistent infection and reinfection.

Antiviral Combinations: What Works?

The study did not specify a single “best” combination, but the findings support the use of combined antiviral approaches in this challenging patient population. A related article published in September 15, 2025 in Infectious Diseases Therapy further supports the use of antiviral combinations for immunocompromised patients with prolonged viral shedding. While the specific regimens used in the study weren’t detailed in the provided materials, the combination of nirmatrelvir and remdesivir, potentially with the addition of monoclonal antibodies, appears to be a promising strategy.

Enhanced Viral Detection Improves Outcomes

Alongside the therapeutic findings, research published concurrently emphasizes the importance of robust viral detection methods. A study detailed in Emerging Infectious Diseases found that using Vero E6 A2T2 cells – a cell line engineered to enhance virus entry and replication – significantly improved the sensitivity of SARS-CoV-2 detection compared to standard Vero E6 cells. This enhanced detection allowed for viral culture up to 7 days after a positive PCR test, compared to only 3 days with standard cell lines. Crucially, the use of Vero E6 A2T2 cells did not appear to promote the development of adaptive mutations in the virus, making it suitable for downstream genomic analysis.

What This Means for Patients and Clinicians

These findings offer a cautiously optimistic outlook for immunocompromised individuals struggling with persistent COVID-19. While the study involved a small cohort, the results suggest that combined antiviral therapy can be a valuable tool for achieving viral clearance and improving clinical outcomes. The ability to overcome pre-existing resistance mutations is particularly encouraging.

However, it’s important to remember that this research is ongoing. Further studies are needed to determine the optimal antiviral combinations, treatment durations, and long-term outcomes. The findings also highlight the need for accurate diagnostic testing, including genomic sequencing, to differentiate between persistent infection and reinfection.

The Role of Oral Antivirals

The American Medical Association has recently emphasized the importance of oral antivirals in treating COVID-19, though the specific details of their recommendations were not provided in the available sources. The use of oral antivirals, in combination with other therapies, may play an increasingly important role in managing COVID-19, particularly in vulnerable populations.

For patients with weakened immune systems who suspect they have a prolonged COVID-19 infection, it is crucial to consult with their healthcare provider to discuss appropriate testing and treatment options. This research underscores the importance of a personalized approach to COVID-19 management, tailored to the individual patient’s immune status and clinical presentation.